Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer

Histology and Histopathology

Volumn 25, Issue 12, 2010, Pages 1497-1506

  Jiang, Xiaohua ^a,b   Gillen, Sonja ^a   Esposito, Irene ^a,c   Giese, Nathalia A ^d   Michalski, Christoph W ^a   Friess, Helmut ^a   Kleeff, Jörg ^a,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SOUTHEAST UNIVERSITY   (China)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytoskeleton; ELF; Pancreatic cancer; Smad; TGF

Indexed keywords

MESSENGER RNA; SPECTRIN; SPTBN1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTRIN; TUMOR MARKERS, BIOLOGICAL;

EID: 79952200834     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Baek H.J., Lim S.C., Kitisin K., Jogunoori W., Tang Y., Marshall M.B., Mishra B., Kim T.H., Cho K.H., Kim S.S. and Mishra L. (2008). Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology 48, 1128-1137.
2. Baines A.J. (2009). Evolution of spectrin function in cytoskeletal and membrane networks. Biochem. Soc. Trans. 37, 796-803.
3. Bennett V. and Baines A.J. (2001). Spectrin and ankyrin-based pathways: Metazoan inventions for integrating cells into tissues. Physiol. Rev. 81, 1353-1392.
4. Chakrabarti A., Kelkar D.A. and Chattopadhyay A. (2006). Spectrin organization and dynamics: New insights. Biosci. Rep. 26, 369-386.
5. Davis L., Abdi K., Machius M., Brautigam C., Tomchick D.R., Bennett V. and Michaely P. (2009). Localization and structure of the ankyrinbinding site on beta2-spectrin. J. Biol. Chem. 284, 6982-6987.
6. Derynck R. and Zhang Y.E. (2003). Smad-dependent and smadindependent pathways in tgf-beta family signalling. Nature 425, 577-584.
7. Erkan M., Reiser-Erkan C., Michalski C.W., Deucker S., Sauliunaite D., Streit S., Esposito I., Friess H. and Kleeff J. (2009). Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11, 497-508.
8. Erkan M., Kleeff J., Gorbachevski A., Reiser C., Mitkus T., Esposito I., Giese T., Buchler M.W., Giese N.A. and Friess H. (2007). Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132, 1447-1464.
9. Esposito I., Seiler C., Bergmann F., Kleeff J., Friess H. and Schirmacher P. (2007). Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment. Pancreas 35, 212-217.
10. Esposito I., Kleeff J., Bergmann F., Reiser C., Herpel E., Friess H., Schirmacher P. and Buchler M.W. (2008). Most pancreatic cancer resections are r1 resections. An. Surg. Oncol. 15, 1651-1660.
11. Friess H., Yamanaka Y., Buchler M., Ebert M., Beger H.G., Gold L.I. and Korc M. (1993). Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105, 1846-1856.
12. Grady W.M. and Markowitz S.D. (2002). Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 3, 101-128.
13. Grum V.L., Li D., MacDonald R.I. and Mondragon A. (1999). Structures of two repeats of spectrin suggest models of flexibility. Cell 98, 523-535.
14. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H. and Kern S.E. (1996). Dpc4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353.
15. Hartwig J.H. (1994). Actin-binding proteins 1: Spectrin superfamily. Protein Profile 1, 706-778.
16. Jemal A., Siegel R., Ward E., Hao Y., Xu J. and Thun M.J. (2009). Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249.
17. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E. and Kinzler K.W. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
18. Katuri V., Tang Y., Marshall B., Rashid A., Jogunoori W., Volpe E.A., Sidawy A.N., Evans S., Blay J., Gallicano G.I., Premkumar Reddy E., Mishra L. and Mishra B. (2005). Inactivation of elf/tgf-beta signaling in human gastrointestinal cancer. Oncogene 24, 8012-8024.
19. Kim S.S., Shetty K., Katuri V., Kitisin K., Baek H.J., Tang Y., Marshall B., Johnson L., Mishra B. and Mishra L. (2006). Tgf-beta signaling pathway inactivation and cell cycle deregulation in the development of gastric cancer: Role of the beta-spectrin, elf. Biochem. Biophys. Res. Commun. 344, 1216-1223.
20. Kitisin K., Ganesan N., Tang Y., Jogunoori W., Volpe E.A., Kim S.S., Katuri V., Kallakury B., Pishvaian M., Albanese C., Mendelson J., Zasloff M., Rashid A., Fishbein T., Evans S.R., Sidawy A., Reddy E.P., Mishra B., Johnson L.B., Shetty K. and Mishra L. (2007). Disruption of transforming growth factor-beta signaling through betaspectrin elf leads to hepatocellular cancer through cyclin d1 activation. Oncogene 26, 7103-7110.
21. Kleeff J., Maruyama H., Friess H., Buchler M.W., Falb D. and Korc M. (1999a). Smad6 suppresses tgf-beta-induced growth inhibition in colo-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem. Biophys. Res. Commun. 255, 268-273.
22. Kleeff J., Ishiwata T., Maruyama H., Friess H., Truong P., Buchler M.W., Falb D. and Korc M. (1999b). The tgf-beta signaling inhibitor smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18, 5363-5372.
23. Klöppel G., Hruban R.H., Longnecker D.S., Adler G., Kern S.E. and Partanen T.J. (2000). Ductal adenocarcinoma of the pancreas. In: Who classification of tumours. Pathology and genetics of tumours of the digestive system. S.R. Hamilton and L.A. Aaltonen (eds). IARC Press. Lyon. pp. 221-230.
24. Loos M., Kleeff J., Friess H. and Buchler M.W. (2008). Approaches to localized pancreatic cancer. Curr. Oncol. Rep. 10, 212-219.
25. Massague J., Blain S.W. and Lo R.S. (2000). Tgfbeta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309.
26. Mishra L., Katuri V. and Evans S. (2005). The role of praja and elf in tgfbeta signaling and gastric cancer. Cancer Biol. Ther. 4, 694-699.
27. Mishra L., Cai T., Yu P., Monga S.P. and Mishra B. (1999). Elf3 encodes a novel 200-kd beta-spectrin: Role in liver development. Oncogene 18, 353-364.
28. Mishra L., Cai T., Levine A., Weng D., Mezey E., Mishra B. and Gearhart J. (1998). Identification of elf1, a beta-spectrin, in early mouse liver development. Int. J. Dev. Biol. 42, 221-224.
29. Mohandas N., Chasis J.A. and Shohet S.B. (1983). The influence of membrane skeleton on red cell deformability, membrane material properties, and shape. Semin. Hematol. 20, 225-242.
30. Mohler P.J. and Bennett V. (2005). Defects in ankyrin-based cellular pathways in metazoan physiology. Front. Biosci. 10, 2832-2840.
31. Reiser-Erkan C., Erkan M., Pan Z., Bekasi S., Giese N.A., Streit S., Michalski C.W., Friess H. and Kleeff J. (2008). Hypoxia-inducible proto-oncogene pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 7, 1352-1359.
32. Siegel P.M. and Massague J. (2003). Cytostatic and apoptotic actions of tgf-beta in homeostasis and cancer. Nat. Rev. Cancer 3, 807-821.
33. Speicher D.W. and Marchesi V.T. (1984). Erythrocyte spectrin is comprised of many homologous triple helical segments. Nature 311, 177-180.
34. Tang Y., Katuri V., Dillner A., Mishra B., Deng C.X. and Mishra L. (2003). Disruption of transforming growth factor-beta signaling in elf beta-spectrin-deficient mice. Science 299, 574-577.
35. Tang Y., Katuri V., Srinivasan R., Fogt F., Redman R., Anand G., Said A., Fishbein T., Zasloff M., Reddy E.P., Mishra B. and Mishra L. (2005). Transforming growth factor-beta suppresses nonmetastatic colon cancer through smad4 and adaptor protein elf at an early stage of tumorigenesis. Cancer Res. 65, 4228-4237.
36. Tang Y., Kitisin K., Jogunoori W., Li C., Deng C.X., Mueller S.C., Ressom H.W., Rashid A., He A.R., Mendelson J.S., Jessup J.M., Shetty K., Zasloff M., Mishra B., Reddy E.P., Johnson L. and Mishra L. (2008). Progenitor/stem cells give rise to liver cancer due to aberrant tgf-beta and il-6 signaling. Proc. Natl. Acad. Sci. USA 105, 2445-2450.
37. Truty M.J. and Urrutia R. (2007). Basics of tgf-beta and pancreatic cancer. Pancreatology 7, 423-435.
38. Wagner M., Kleeff J., Friess H., Buchler M.W. and Korc M. (1999). Enhanced expression of the type ii transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19, 370-376.
39. Welsch T., Kleeff J. and Friess H. (2007). Molecular pathogenesis of pancreatic cancer: Advances and challenges. Curr. Mol. Med. 7, 504-521.
40. Xu Y. and Pasche B. (2007). Tgf-beta signaling alterations and susceptibility to colorectal cancer. Hum. Mol. Genet. 16 Spec No 1, R14-20.
41. Accepted May 17, 2010